amatuximab: Clinical Trials

7 trials of amatuximab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 terminated. 3 Phase 1, 3 Phase 2, 1 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 13Completed 3
Phase 23Completed 2, Terminated 1
Early Phase 11Terminated 1

Follow amatuximab: new trials by email Literature Review of amatuximab trials Research Report on amatuximab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)
Placebo, Amatuximab, Pemetrexed - Mesothelioma, Malignant
Phase 2TerminatedMorphotek1242015-11-032020-03-17
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
Amatuximab - Mesothelioma, Pancreatic Cancer
Phase 1CompletedMorphotek62011-09-012016-09-30
Amatuximab for High Mesothelin Cancers
Amatuximab (MORab-009) - Carcinoma, Pancreatic Ductal, Mesothelioma
Early Phase 1TerminatedNational Cancer Institute (NCI)72011-07-122019-12-17
A Study of MORAb-009 in Patients With Solid Tumor
MORAb-009 - Cancer, Mesothelin-positive
Phase 1CompletedEisai Co., Ltd.172009-11-012016-01-21
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
MORAb-009 (Amatuximab), Pemetrexed, Cisplatin - Malignant Pleural Mesothelioma
Phase 2CompletedMorphotek892008-12-312022-09-22
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
MORAb-009, Placebo, Gemcitabine - Pancreatic Cancer
Phase 2CompletedMorphotek1552007-12-012015-09-09
A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer
MORAb-009 - Pancreatic Cancer, Mesothelioma
Phase 1CompletedMorphotek242006-05-012014-07-17

Conditions studied

Carcinoma, Non-Small-Cell Lung (3)  ·  Mesothelioma (3)  ·  Ovarian Neoplasms (3)  ·  Pancreatic Neoplasms (3)  ·  Mesothelioma, Malignant (2)  ·  Carcinoma, Pancreatic Ductal (1)  ·  Neoplasms (1)  ·  Severe combined immunodeficiency with sensitivity to ionizing radiation (1)

Sponsors

Morphotek (5)  ·  Eisai Co., Ltd. (1)  ·  National Cancer Institute (NCI) (1)

Countries

United States (6)  ·  Germany (3)  ·  Canada (2)  ·  Spain (2)  ·  Australia (1)  ·  Belgium (1)  ·  France (1)  ·  Italy (1)  ·  Japan (1)  ·  Netherlands (1)  ·  United Kingdom (1)

Top investigators

Bruce Wallin, MD (1)  ·  Chifumi Kitamura (1)  ·  Raffit Hassan, M.D. (1)  ·  Raffit Hassan, MD (1)  ·  Susan C. Weil, M.D. (1)

Results publications

PMID 25502863

NIH funding

2008 (1), 2014 (1)